Sun Pharmaceutical Industries subsidiary Sun Pharma Advanced Research Company (SPARC) has informed stock exchanges that its licensing partner, Ocuvex Therapeutics Inc., received a Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) of PDP-716.
The update has placed Sun Pharmaceutical Industries shares in focus as investors track regulatory developments related to the drug candidate.
USFDA Raises Manufacturing-Related Observations
According to the regulatory filing, the USFDA’s CRL was linked specifically to inspection-related observations at the finished product manufacturing facility.
SPARC clarified that:
- No additional concerns were raised regarding the clinical efficacy or scientific aspects of the NDA
- The observations were restricted to the manufacturing site involved in product production
A Complete Response Letter is issued when the regulator determines that an application cannot be approved in its current form and requires corrective actions or additional information before approval can proceed.
PDP-716 Under Regulatory Review
PDP-716 is a drug candidate licensed to Ocuvex Therapeutics for regulatory development and commercialisation.
The NDA had been submitted to the USFDA for review, but the latest response means the applicant will now need to:
- Address manufacturing observations
- Complete required corrective measures
- Resubmit the application for further review
The companies have not yet disclosed a revised approval timeline.
Market Sentiment Remains Cautious
Regulatory observations related to manufacturing facilities are closely watched in the pharmaceutical sector because they can:
- Delay product approvals
- Impact commercial launch timelines
- Affect future revenue expectations
Following the announcement, investor sentiment around SPARC remained cautious.
Sun Pharma Share Price Performance
As of May 20, 2026, at 10:59 AM, SUNPHARMA was trading at ₹1,887.10 compared to the previous close of ₹1,882.30, gaining ₹4.80 or 0.26% during the session.
Conclusion
The USFDA’s Complete Response Letter for PDP-716 represents a regulatory hurdle for Sun Pharma Advanced Research Company and its partner Ocuvex Therapeutics Inc..
While the regulator did not raise concerns regarding the drug’s clinical profile, the manufacturing-related observations will need to be resolved before the approval process can move forward.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.